Valeritas’ wearable insulin delivery device lowers total daily insulin dose
Valeritas (NSDQ:VLRX) highlighted real-world clinical outcomes and economic data for its V-Go wearable insulin delivery device at this year’s ADA meeting.
The company presented data from a prospective 415-patient trial, which evaluated V-Go compared to standard treatment in patients with Type II diabetes. Patients were enrolled and treated for up to 4 months and those who used the V-Go device stopped all other insulin therapy.
The study’s primary outcome was the difference in the change in blood sugar levels from baseline to the end of the study.
The company reported that V-Go improved A1C and decreased the total daily insulin dose from 71.3 units per day to 54 units per day. The dose for patients who received standard treatment remained unchanged at 72 units per day.
In a retrospective study, Valeritas found that persistent use of V-Go helped lower a patient’s daily dose of insulin and was more cost-effective than conventional insulin delivery.
Finally, the company also reported that patients using V-Go had a larger reduction baseline A1C than standard of care.
“There are a significant number of patients with Type II diabetes who are prescribed multiple daily injections of insulin who far exceed the recommended A1C goals,” president & CEO John Timberlake said in prepared remarks. “The results presented at this ADA meeting further demonstrate that use of V-Go can provide significant and meaningful clinical and economic benefits, and reduce the total daily insulin dose in patients with Type II diabetes compared to regimens with insulin injections. Insulin works when the patient takes it and Valeritas continues to demonstrate how V-Go can provide benefits for patients with Type II diabetes in a simple to train and simple to use wearable insulin delivery device.”
